Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

February 12, 2024

Study Completion Date

May 6, 2024

Conditions
Nonproliferative Diabetic Retinopathy
Interventions
DRUG

EYP-1901

EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle. Each EYP-1901 IVT insert has been designed to deliver vorolanib into the vitreous humor for approximately 6 to 9 months.

OTHER

Sham IVT

Sham injections will be used to maintain masking of investigational EYP-1901 therapy for study subjects.

Trial Locations (36)

11021

EyePoint Investigative Site, Great Neck

16501

EyePoint Investigative Site, Erie

21209

EyePoint Investigative Site, Baltimore

21740

EyePoint Investigative Site, Hagerstown

24502

EyePoint Investigative Site, Lynchburg

29456

EyePoint Investigative Site, Ladson

29501

EyePoint Investigative Site, Florence

32901

EyePoint Investigative Site, Melbourne

33143

EyePoint Investigative Site, Miami

33761

EyePoint Investigative Site, Clearwater

33880

EyePoint Investigative Site, Winter Haven

38138

EyePoint Investigative Site, Germantown

46290

EyePoint Investigative Site, Indianapolis

57701

EyePoint Investigative Site, Rapid City

60439

EyePoint Investigative Site, Lemont

66215

EyePoint Investigative Site, Lenexa

75075

EyePoint Investigative Site, Plano

77384

EyePoint Investigative Site, The Woodlands

78240

EyePoint Investigative Site, Houston

78247

EyePoint Investigative Site, San Antonio

78503

EyePoint Investigative Site, McAllen

78705

EyePoint Investigative Site, Austin

79606

EyePoint Investigative Site, Abilene

85020

EyePoint Investigative Site, Phoenix

89502

EyePoint Investigative Site, Reno

90041

EyePoint Investigative Site, Pasadena

92064

EyePoint Investigative Site, Poway

92211

EyePoint Investigative Site, Palm Desert

92647

EyePoint Investigative Site, Huntington Beach

93036

EyePoint Investigative Site, Oxnard

95825

EyePoint Investigative Site, Sacramento

98004

EyePoint Investigative Site, Bellevue

06810

EyePoint Investigative Site, Danbury

01107

EyePoint Investigative Site, Springfield

07003

EyePoint Investigative Site, Bloomfield

08755

EyePoint Investigative Site, Toms River

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY

NCT05383209 - Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) | Biotech Hunter | Biotech Hunter